• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    Imperial Tobacco Canada

    企业
    45论文总数
    706引用总数

    Imperial Tobacco Canada Limited is a cigarette manufacturing company operating in Canada. It is a wholly owned subsidiary of British American Tobacco. It was created in 1908 and bought out the Canadian interests of the American Tobacco Company, which was a monopoly in the United States until it was reorganized in 1911. Imperial Tobacco Canada has had no relationship to Imperial Tobacco Group plc since 1980, though British American Tobacco was established as a joint venture between Imperial Tobacco Group and American Tobacco. Imasco sold their stake to BAT in 2000..

    论文量&引用量时间轴

    机构学者

    排序
    andre morin
    andre morin
    论文:9引用:0H-index:0
    Jean-Philippe Roy
    Jean-Philippe Roy
    Imperial Tobacco Canada Ltd
    论文:4引用:0H-index:0
    Richard Voisine
    Richard Voisine
    Imperial Tobacco Canada Limited
    论文:4引用:0H-index:0
    Martine Lacasse
    Martine Lacasse
    Imperial Tobacco Canada Ltd
    论文:3引用:0H-index:0
    Sébastien Talbot
    Sébastien Talbot
    Faculty of Medicine, Université de Montréal
    论文:3引用:0H-index:0
    Karen C. Waldron
    Karen C. Waldron
    Chemistry, University of Alberta
    论文:3引用:0H-index:0
    James Chi-Jen Lin
    James Chi-Jen Lin
    Imperial Tobacco Canada Ltd
    论文:3引用:0H-index:0
    Rejean Couture
    Rejean Couture
    Faculty of Medicine, Université de Montréal
    论文:3引用:0H-index:0
    O'Connell Grant
    O'Connell Grant
    Group Science and Regulatory Affairs, Imperial Brands PLC
    论文:3引用:0H-index:0

    论文(45)

    年份
    起
    –
    止
    排序
    1P30-101 in Vitro Biocompatibility Assessment of Nicotine Pouches to Support Regulatory Safety Evaluation
    S. Bozhilova, E. Bishop, D. Azzopardi, G. Mullard, D. Breheny
    2026Toxicology Letters(2026)
    引用
    AI阅读
    加入学术空间
    2A Randomised Study to Assess the Nicotine Pharmacokinetics of an Oral Nicotine Pouch and Two Nicotine Replacement Therapy Products
    David Azzopardi,James Ebajemito,Michael McEwan,Oscar M. Camacho,Jesse Thissen,George Hardie,Richard Voisine,Gavin Mullard, Zvi Cohen,James Murphy

    Nicotine replacement therapies (NRTs) are intended for short-term use to help cigarette smokers to quit. Some smokers find NRTs ineffective or seek a more satisfactory source of nicotine. Tobacco-free oral nicotine pouch (NP) products have emerged as a potential reduced risk product compared with cigarettes and other tobacco products. In a randomised crossover clinical study, thirty-four healthy adult smokers were enrolled and their nicotine Cmax and AUC0-T determined for three 4 mg nicotine products (NP, gum, lozenge) under fasting conditions. The NP, lozenge and gum mean Cmax values were 8.5, 8.3 and 4.4 ng/mL, AUC0-T values were 30.6, 31.5 and 14.3 ng*h/mL, respectively. The NP showed similar nicotine bioavailability to the lozenge (p = 0.6526 (Cmax), p = 1.0000 (AUC0-T)), and superior bioavailability to the gum (p < 0.0001 for Cmax and AUC0-T). Compared with the lozenge, the NP demonstrated greater product satisfaction with a higher number of positive responses to subjective satisfaction questions. All products were judged to be well-tolerated; the incidence of minor adverse events was lower for the NP (18.2%) than the lozenge (33.3%) or gum (18.8%). In summary, NPs may provide smokers with a more satisfying alternative nicotine source as compared to the reference NRTs. Study Registry/Registered Trial No: ISRCTN/ISRCTN65708311.

    2022Scientific Reports(2022)引用:33
    引用
    AI阅读
    加入学术空间
    3An in Vitro Approach to E-Cigarette Toxicity Testing
    L. Simms,L. Czekala,M. Stevenson, G. Phillips, R. Tilley, K. Rudd, T. Walele
    2018TOXICOLOGY LETTERS(2018)
    引用
    AI阅读
    加入学术空间
    4The in Vitro Assessment of Respiratory Sensitisation Potential of Electronic Cigarette Liquids
    M. Stevenson,L. Czekala,L. Simms, N. Tschierske,H. Johansson, T. Walele

    Experimental studies clearly demonstrate a causal effect of cigarette smoking on cardiovascular disease. To reduce the individual risk and population harm caused by smoking, alternative products to cigarettes are being developed. We recently reported on an apolipoprotein E-deficient (Apoe−/-) mouse inhalation study that compared the effects of exposure to aerosol from a candidate modified risk tobacco product, Tobacco Heating System 2.2 (THS2.2), and smoke from the reference cigarette (3R4F) on pulmonary and vascular biology. Here, we applied a transcriptomics approach to evaluate the impact of the exposure to 3R4F smoke and THS2.2 aerosol on heart tissues from the same cohort of mice. The systems response profiles demonstrated that 3R4F smoke exposure led to time-dependent transcriptomics changes (False Discovery Rate (FDR) < 0.05; 44 differentially expressed genes at 3-months; 491 at 8-months). Analysis of differentially expressed genes in the heart tissue indicated that 3R4F exposure induced the downregulation of genes involved in cytoskeleton organization and the contractile function of the heart, notably genes that encode beta actin (Actb), actinin alpha 4 (Actn4), and filamin C (Flnc). This was accompanied by the downregulation of genes related to the inflammatory response. None of these effects were observed in the group exposed to THS2.2 aerosol.

    2018Toxicology Letters(2018)
    引用
    AI阅读
    加入学术空间
    5Assessment of Nicotine Exposure from Active Human Cigarette Smoking Time
    Xavier Cahours,Rémi Julien,Thomas Verron,Stéphane Colard

    Summary The burning of a cigarette is a series of consecutive sequences of both passive and active burnings when a smoking cycle is applied to the cigarette. A previous study, using a smoking machine, showed that cigarette nicotine yields are dependent linearly on the difference between the time of smouldering (passive burning) and the time of smoking (active burning). It is predicted that the smoker’s nicotine yield increases when the intensity of smoking increases, i.e., when the time to smoke a cigarette (smoking time) decreases. Note that observations made on machines might not be comparable to human behaviours. The aim of this study was to determine whether nicotine mouth-level exposure could be predicted through measurement of human smoking time. A smoking behaviour study was conducted to compare human smoking nicotine yields obtained from both filter tip analysis and the cigarette burning time model. Results showed that smokers’ exposure to the smoke depends essentially on the speed at which the cigarette is smoked. An increase in human smoking intensity, resulting in a decrease in smoking time, generates an increase in smoke exposure, whatever the puff number, puff duration, puff volume and filter ventilation (open or blocked). The association of a machine smoking yield with a corresponding smoking time, and the time taken by a consumer to smoke the cigarette would provide information on the exposure to smoke constituents in a simple and effective manner.

    2017Beiträge zur Tabakforschung International/Contributions to Tobacco Research(2017)引用:2
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 45 篇论文

    合作机构(10)

    蒙特利尔大学合作论文 6
    英美烟草公司合作论文 6
    农业与农业食品加拿大部合作论文 4
    Reemtsma合作论文 1
    National Research Council Canada合作论文 1
    R. J. Reynolds Tobacco Company合作论文 1
    HCL Technologies Inc.合作论文 1
    魁北克大学蒙特利尔分校合作论文 1
    蒙特利尔高等商学院合作论文 1
    帝国烟草合作论文 1

    机构统计